Skip to main content
Premium Trial:

Request an Annual Quote

Gene Express Licenses USF IP for Lung Cancer Predictive Test

NEW YORK (GenomeWeb News) – Gene Express said Monday that it has licensed technology from the University of South Florida that it will use to develop a prognostic test to be used in the treatment of lung cancer.
 
The company licensed gene expression technology related to the ERCC1 and RRM1 genes from USF’s Division of Patents & Licensing Research Office.
 
USF researchers have found that ERCC1 activity can be used to predict survival in patients with non-small cell lung cancer and have found that RRM1 is a determinant of malignant behavior in NSCLC.
 
Gene Express said USF’s scientists have determined that knowing the level of expression of RRM1 allows for better-informed decisions than currently used predictors of tumor stage, performance status, and weight loss.
 
The Toledo, Ohio-based company said it plans to develop the prognostic test and commercialize it over the next two years.
 
Gene Express expects to complete clinical validation to correlate gene expression with chemoresistance for cisplatin treatment and to submit a 510(k) class II prognostic test to the US Food and Drug Administration by May 2009. The firm hopes to obtain approval from the FDA by August 2009 and have the test on the market by the end of next year.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.